Search

… ProQR Announces Fourth Quarter and Full Year 2019 Results and … & CAMBRIDGE, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … 2020,” said Daniel A. de Boer, Chief Executive Officer of ProQR. “In 2019 we shared positive Phase 1/2 data for …

… ProQR Announces Webcast of Presentation at Upcoming HC … on demand from the “Investors & Media” section of ProQR’s website ( www.proqr.com ) under ‘Events’, beginning March 9, 2021. …

… ProQR Announces Recent Progress and Financial Results for the … & CAMBRIDGE, Mass., Nov. 06, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … said Daniel A. de Boer, chief executive officer of ProQR. “In October we announced that LCA10 patients …

… ProQR to Present at Cowen and Company 40th Annual Health Care … will be accessible from the “Investors” section of ProQR’s website ( www.proqr.com ) under ‘Events and Presentations’. The …

… ProQR Announces Publication in Nature Medicine for Sepofarsen … & CAMBRIDGE, Mass., April 13, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR ), a company dedicated … vision,” said Aniz Girach, MD, Chief Medical Officer of ProQR, “The visual field improvements observed indicate that …

… ProQR to Present at the Leerink Partners 4th Annual Rare … be accessible from the 'Investor Relations' section of ProQR's website ( www.proqr.com ) under 'Events and Presentations'. The …

… ProQR Announces Expert Perspectives Call on Disease Education … & CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … between Aniz Girach, MD, Chief Medical Officer of ProQR Therapeutics and Paul Yang, MD, PhD about disease …

… ProQR Completes Dosing of Cystic Fibrosis Patients in QR-010 … including sweat chloride, weight gain, change in CFQ-R Respiratory Symptom Score and FEV 1 , however, the study is … said Noreen R. Henig MD, Chief Medical Officer at ProQR. “We are grateful to the patients and the medical …

… ProQR Receives Fast Track Designation from FDA for QR-010 for … faster,” said Daniel de Boer, Chief Executive Officer of ProQR. “We are also looking forward to releasing data for the … in this study include sweat chloride, weight gain, CFQ-R Respiratory Symptom Score and lung function, measured by …

… ProQR Initiates Phase 1/2 Clinical Trial of QR-313 for … LEIDEN, the Netherlands, June 28, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … Executive Vice President of Research and Development at ProQR. “Now that the study is initiated we expect to dose the …